Publications by authors named "Funan Huang"

Claim this Profile
S
Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors.
Benedito A Carneiro, Robert M Jotte, Nashat Y Gabrail, Kristopher Wentzel, Funan Huang

Cancer Res Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
Weiping Liu, Lingyan Ping, Yan Xie, Yingli Sun, Tingting Du, Funan Huang

Cancer Chemother Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.
Christian Zurth, Pirjo Nykänen, Gary Wilkinson, Päivi Taavitsainen, Annamari Vuorela, Funan Huang

Clin Pharmacokinet· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.
Ola Lindén, Andrew T Bates, David Cunningham, Cecilia Hindorf, Erik Larsson, Funan Huang

Cancer Biother Radiopharm· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
Colin Weekes, A Craig Lockhart, James J Lee, Isrid Sturm, Adriaan Cleton, Funan Huang

Int J Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer.
Selina K Wong, Quincy S C Chu, Jennifer L Spratlin, Randeep Sangha, Alexander J B McEwan, Funan Huang

Case Rep Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.
Joachim Grevel, Garrit Jentsch, Rupert Austin, Nicolaas H Prins, John Lettieri, Funan Huang

Clin Transl Sci· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
Frederik Marmé, Carlos Gomez-Roca, Kristina Graudenz, Funan Huang, John Lettieri

Cancer Chemother Pharmacol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Funan Huang, Antoinette Ajavon, Erya Huang, John Lettieri, Rong Liu

Thyroid· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of lead exposure on proliferation and differentiation of neural stem cells derived from different regions of embryonic rat brain.
Funan Huang, J S Schneider

Neurotoxicology· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of ATP levels alters the mode of hydrogen peroxide-induced cell death in primary cortical cultures: effects of putative neuroprotective agents.
Funan Huang, Mohan C Vemuri, J S Schneider

Brain Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis